Improving Detection Limits of ADC Free-Drug Impurities Using the ACQUITY QDa Mass Detector

Significance of the Topic

Antibody–drug conjugates (ADCs) have emerged as a cutting-edge immunotherapy modality that harnesses the specificity of monoclonal antibodies to deliver highly potent cytotoxic agents directly to tumor cells. Ensuring the safety and efficacy of these biotherapeutics demands rigorous monitoring of residual free-drug impurities, which can compromise the therapeutic window by introducing off-target toxicity. Traditional UV-based assays often lack the sensitivity and dynamic range needed to detect trace-level contaminants in formulated ADC products.

Objectives and Study Overview

This study aimed to evaluate whether coupling a mass detector (ACQUITY QDa) in-line with an ultraperformance liquid chromatography (UPLC) system could dramatically extend the dynamic range and lower the detection limits for free-drug impurities compared to conventional UV detection. A surrogate ADC drug molecule (NAc-linker-DSEA) was serially diluted and analyzed to quantify assay performance.

Methodology and Used Instrumentation

Reversed-phase liquid chromatography (RPLC) was employed using a superficially porous CORTECS RP column (2.1 × 50 mm, 2.7 µm). The chromatography system featured an ACQUITY UPLC H-Class Bio System equipped sequentially with:

• ACQUITY TUV UV detector
• ACQUITY QDa single-quadrupole mass detector

Selected ion recording (SIR) monitored the [M+2H]2+ charge state of the payload. A series of 1:1 dilutions of the monomethyl auristatin E-based surrogate (MW 1167.5 Da) was injected (10 µL) to establish limits of quantitation (LOQ) and dynamic range.

Main Results and Discussion

The integration of MS detection extended assay sensitivity by over two orders of magnitude. The QDa detector achieved an LOQ of 0.33 ng/mL (1.65 pg on-column, S/N=10), compared to 85 ng/mL with UV alone—a 250-fold improvement. In a post-purified ADC sample (1.94 mg/mL), the free-drug impurity concentration of 7.2 ng/mL was readily quantified by MS but fell below the UV detection threshold. This enhanced performance underlines the critical role of MS-based detection in capturing low-level contaminants that could impact patient safety.

Benefits and Practical Applications

The combined UPLC–QDa approach delivers several advantages for ADC characterization and quality control:

• Sub-nanogram LOQs support stringent impurity specifications.
• Broad dynamic range accommodates both trace-level and higher concentration analyses without reconfiguration.
• Rapid method development leveraging existing RPLC workflows.
• Scalable solution for routine QC labs in biopharmaceutical production.

Future Trends and Possibilities

As ADC pipelines expand, the following trends are anticipated to further enhance impurity profiling:

• Integration of high-resolution MS for structural elucidation of unknown degradants.
• Automation and high-throughput screening workflows to increase sample capacity.
• Data-driven analytics combining MS datasets with machine learning for predictive impurity profiling.
• Miniaturized and microfluidic LC–MS systems to reduce sample consumption and solvent usage.

Conclusion

The ACQUITY QDa mass detector, when coupled in-line with UPLC, provides a robust, sensitive, and scalable assay for detecting free-drug impurities in ADC formulations. By extending detection limits and dynamic range well beyond UV-only methods, this approach strengthens product safety and supports the development of next-generation biotherapeutics.

References

No literature references were provided in the source document.